Roche Report Results of Ab Cocktail (Casirivimab + Imdevimab) in P-III REGN-COV 2069 Trial for Symptomatic COVID 19 Infection

April 12, 2021 Auto Bot Casirivimab, Clinical Trials, Imdevimab, Report, results, Roche 0

Shots:

  • The P-III REGN-COV 2069 trial involves assessing the efficacy and safety of Ab cocktail (casirivimab (1200 mg, SC) + imdevimab (1200 mg, SC) vs PBO in 1,505 people to prevent symptomatic infection in household contacts of individuals infected with COVID-19
  • The trial met its 1EP and 2EPs showed an 81% reduction in the risk of symptomatic infections, patients with symptomatic infection resolved symptoms (1 vs 3wk.). In a cohort of infected asymptomatic patients, Ab cocktail showed a 31% reduction in the overall risk of progressing to symptomatic COVID-19
  • The companies will share the results with regulatory authorities including the EMA and the FDA

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Visao

The post Roche Report Results of Ab Cocktail (Casirivimab + Imdevimab) in P-III REGN-COV 2069 Trial for Symptomatic COVID 19 Infection first appeared on PharmaShots.